The VaSecure BTK Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-30

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the safety and performance of the VaSecure drug-coated PTA balloon catheter in the treatment of patients with Chronic Limb Threatening Ischemia (CLTI) of the lower limb below the knee (BTK)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ILLUMENATE Below-The-Knee (BTK) Arteries: a Post Market Clinical Study

NCT03395236

Peripheral Arterial Disease

COMPLETED PHASE4

The PRELUDE BTK Study

NCT03693963

Peripheral Arterial Disease Critical Limb Ischemia

COMPLETED NA

Lutonix DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries

NCT01870401

Critical Limb Ischemia

COMPLETED NA

The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia

NCT03551496

Critical Limb Ischemia

COMPLETED PHASE3

Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon for Treatment of BTK Arteries

NCT02554266

Peripheral Artery Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The VaSecure Drug Coated PTA Balloon Catheter is indicated for percutaneous transluminal angioplasty (PTA), after predilatation, of de novo lesions in the peripheral vasculature of the lower limb with reference vessel diameters of 2-4 mm.

The study will include patients with lesions located in the infrapopliteal arteries diagnosed with CLTI of Rutherford categories 3-5. A maximum number of 46 patients will be enrolled in this clinical investigation in 7 sites in Europe and 2 in Singapore.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Artery Disease Peripheral Vascular Disease Peripheral Arterial Occlusive Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VaSecure™ Drug Coated PTA Balloon Catheter

Group Type EXPERIMENTAL

VaSecure™

Intervention Type DEVICE

Drug Coated PTA Balloon Catheter

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VaSecure™

Drug Coated PTA Balloon Catheter

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Able to provide written informed consent prior to participating in the clinical investigation, e.g. patients are mentally able to understand the aim of the clinical investigation.
2. Has a documented diagnosis of CLTI of Rutherford category 3-5.
3. The target lesion must be de novo.
4. Life expectancy is \>1 year, in the investigator's opinion.
5. For women: menopausal or under active birth control.
6. Patient must agree not to participate in any other clinical trial during 12 month follow-up period.

7. Reference vessel(s) diameter is between 2mm-4mm. Each lesion in one or maximum two of the infrapopliteal arteries NOT extending beyond the ankle joint. Target lesion(s) consisting of a single solitary or series of multiple adjacent lesions (all less than 30 mm apart) in a single tibial vessel with a diameter stenosis ≥70% and a cumulative length of ≥50 mm to ≤250 mm. If there are two target lesions they will be separated for ≥3 cm and will be named from proximal to distal. Target lesion must be a tibial vessel (excluding popliteal artery) branching from popliteal artery.

Exclusion Criteria

1. Breastfeeding or pregnant woman.
2. Severe concentric calcification, documented by angiography using the COMPLIANCE360-Score (This scoring system takes into account both the arc of calcium (\< or \> 180º) and percent of lesion length (\< or \> 50%) as judged by fluoroscopy.) that could not be fully expanded by predilatation balloon and documented by angiography. Valid record up to 30 days before screening.
3. Patients with major amputations that have already been performed or are planned, either on the target leg or on the contralateral side. .
4. History of stroke within 3 months.
5. History of myocardial infarction, thrombolysis or angina within 30 days prior to index procedure.
6. Renal failure or chronic kidney disease with estimated Glomerular Filtration Rate (eGFR) ≤30 mL/min per 1.73 m2 (or serum creatinine ≥2.5 mg/dL within 30 days of index procedure or treated with dialysis).
7. Diagnosed active untreated systemic infection or uncontrolled coagulopathy within 14 days prior to index procedure.
8. Co-morbid conditions limiting life expectancy to \<12 months.
9. Hemorrhagic diathesis or another disorder such as gastrointestinal ulceration or cerebral circulatory disorders which restrict the use of platelet aggregation inhibitor therapy and anticoagulation therapy.
10. Known allergy to paclitaxel or paclitaxel-related compounds or contrast media that cannot be adequately managed with pre- and post-procedure medication.
11. Is currently participating in an investigational drug or other investigational device study or previously enrolled in this study.
12. Is unlikely to comply with the follow up schedule.
13. Has uncontrolled ulcer wound infection.
14. Is unwilling to comply with a concurrent ulcer wound therapy.
15. Has an allergy to acetylsalicylic acid, prasugrel, ticagrelol, and clopidogrel (Plavix®).
16. Use of atherectomy in proximal vessels or TL. However, the use of scoring/cutting balloons in the TL is allowed.

17. Lesions that cannot be successfully predilated to achieve a residual stenosis of \<50% by visual estimate.
18. Severe dissection post dilatation resulting in a flow limiting lesion.
19. Thrombus in the target vessel documented by angiography.
20. Aneurysm in the target vessel(s).
21. Treatment of the contralateral limb during the same index procedure or within 30 days post-index procedure in order to avoid confounding complications.

Minimum Eligible Age

21 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No